GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 35 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $200,000 | – | 15,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 2,890,102 | $9,306,000 | 0.72% |
| Orbimed Advisors | 7,884,870 | $25,389,000 | 0.47% |
| GREAT POINT PARTNERS LLC | 449,049 | $1,446,000 | 0.35% |
| Vivo Capital, LLC | 961,359 | $3,096,000 | 0.34% |
| Capital International, Inc./CA/ | 3,016,371 | $9,713,000 | 0.22% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $31,884,247 | 0.19% |
| EcoR1 Capital, LLC | 1,921,310 | $6,187,000 | 0.18% |
| Capital International Sarl | 304,582 | $981,000 | 0.08% |
| FEDERATED HERMES, INC. | 1,298,578 | $4,181,000 | 0.01% |
| Cannell Capital | 14,299 | $46,000 | 0.01% |